TL;DR
Neurodegenerative diseases share common protein pathologies, but how these proteins spread between cells and affect neuronal function is unclear. This study systematically compares the release and uptake of alpha-synuclein, Tau, and huntingtin, revealing common release pathways and distinct effects on neuronal activity, suggesting new therapeutic targets.
What Problem Does This Paper Address?
Several neurodegenerative diseases, like Parkinson's, Alzheimer's, and Huntington's, are characterized by the accumulation and spread of misfolded proteins: alpha-synuclein (aSyn), Tau, and huntingtin (Htt), respectively. While it's known these proteins can transfer from cell to cell, the precise mechanisms of this transfer and how they impact neuronal function remain poorly understood. This lack of clarity hinders the development of effective therapies. This paper aims to systematically compare how these three key disease-associated proteins are released from cells, how they are taken up by other cells, and what functional consequences these processes have, particularly on neuronal activity.
Methods
The researchers employed a multi-pronged approach:
- Cell Culture Models: They used stable HEK cell lines engineered to express fluorescently tagged versions of aSyn, Tau, and huntingtin (both wild-type and mutant forms with varying polyglutamine lengths). They also used primary cortical neurons, microglia, and astrocytes.
- Protein Release Assays: They measured the levels of these proteins in both cell lysates and the extracellular media to quantify their release.
- Extracellular Vesicle (EV) Isolation and Analysis: They used differential ultracentrifugation to isolate ectosomes and exosomes from cell culture media. These EVs were then analyzed for protein content and characterized using electron microscopy and nanoparticle tracking analysis.
- USP19 Co-expression: To investigate the role of the misfolding-associated protein secretion pathway (MAPS), they co-expressed disease proteins with USP19, a protein involved in this pathway.
- EV Internalization Assays: They incubated glial cells (microglia and astrocytes) and neurons with EVs containing the disease proteins and assessed uptake using microscopy and flow cytometry.
- Neuronal Activity Recording: Multi-electrode arrays (MEAs) were used to record the spontaneous electrical activity of primary cortical neurons after treatment with either EVs or free monomeric proteins.
- Biochemical Assays: Standard techniques like Western blotting, SDS-PAGE, and LDH cytotoxicity assays were used to confirm protein levels, purity, and absence of toxicity.
- Gene Expression Analysis: qPCR was used to measure the expression of inflammatory markers in glial cells.
Datasets
Not explicitly discussed as "datasets" in the context of machine learning. The study utilized data generated from their own experiments using the cell models and techniques described above.
Key Insights and Ideas
- Common Release Pathways, Different Levels: Despite being associated with different diseases, aSyn, Tau, and Htt are released from cells via similar molecular pathways. However, the levels of release vary, with shorter huntingtin (25QHtt), aSyn, and Tau being released more readily than longer huntingtin (103QHtt).
- USP19 as a Secretion Enhancer: The protein USP19, implicated in unconventional protein secretion, can significantly boost the release of disease-related proteins, particularly huntingtin.
- Ectosomes Dominate Protein Cargo: Disease-related proteins are found at higher concentrations in ectosomes compared to exosomes, suggesting ectosomes might play a more significant role in their intercellular spread.
- EVs Trigger Glial Responses: When microglia and astrocytes internalize EVs containing these proteins, they exhibit increased pro-inflammatory cytokine production and autophagy activation, regardless of the specific protein cargo. This suggests a general response to EV uptake by immune cells.
- Protein Properties Matter More Than Levels for Neuronal Effects: While the levels of protein release differ, the intrinsic properties of the proteins (aSyn, Tau, Htt) seem to be more critical in modulating neuronal activity than the sheer quantity present extracellularly.
- Distinct Neuronal Modulation: Monomeric aSyn, Tau, and Htt have specific and differential effects on neuronal firing patterns. Tau, for instance, appears to increase neuronal activity and synchronization, while Htt (especially the expanded form) can be detrimental.
Key Results
- Differential Release: 25QHtt-EGFP, aSyn-EGFP, and EGFP-Tau were released at higher levels than 103QHtt-EGFP from HEK cells and primary neurons.
- USP19 Boost: USP19 expression significantly increased the secretion of 25QHtt-EGFP.
- EV Enrichment: Disease-related proteins were found at higher levels in ectosomes than in exosomes.
- Glial Activation: EV uptake by microglia and astrocytes led to increased IL-6, IL-1β, and TNFα production, and increased autophagy markers.
- Neuronal Activity Modulation:
- EVs generally disrupted synchronized neuronal bursting, leading to more irregular spiking.
- Monomeric Tau increased neuronal activity and synchronization.
- Monomeric aSyn showed slight alterations in activity.
- Monomeric Htt (especially 43QHtt) reduced spike amplitude and altered bursting patterns, suggesting toxicity.
Limitations and Future Work
- Cell-Specific Responses: While common pathways exist, the study notes that receptor cells handle protein uptake and effects differently, highlighting the need for further investigation into cell-type-specific mechanisms.
- EV Content Complexity: The study focused on protein cargo. Future work should explore how other biomolecules within EVs (lipids, nucleic acids) might influence uptake and cellular responses.
- Therapeutic Implications: The authors emphasize that while these proteins and EVs are involved in pathology, careful consideration is needed to develop therapies that target disease progression without interfering with normal intercellular communication.
- In Vivo Relevance: While cell-based models are powerful, future studies should aim to validate these findings in more complex in vivo models to fully understand the implications for neurodegenerative diseases.
Summary updated